Forkhead Box Q1 Expression Is Associated With Tumor Location of Right-Sided Colon, But Not With Acquisition of Oxaliplatin Resistance in Colorectal Cancer

Tomoki Yamano (✉ yamanot@hyo-med.ac.jp)  
Hyogo College of Medicine

Shuji Kubo  
Hyogo College of Medicine

Tomoko Kominato  
Hyogo College of Medicine

Aya Yano  
Hyogo College of Medicine

Yuya Takenaka  
Hyogo College of Medicine

Jihyung Son  
Hyogo College of Medicine

Kei Kimura  
Hyogo College of Medicine

Michiko Yasuhara  
Hyogo College of Medicine

Akihito Babaya  
Hyogo College of Medicine

Kozo Kataoka  
Hyogo College of Medicine

Naohito Beppu  
Hyogo College of Medicine

Masataka Ikeda  
Hyogo College of Medicine

Kazuto Nishio  
Kindai University

Naohiro Tomita  
Hyogo College of Medicine

Research Article

Keywords: FOXQ1, drug resistance, oxaliplatin, colorectal cancer, tumor location

DOI: https://doi.org/10.21203/rs.3.rs-154413/v1
Abstract

Oxaliplatin (OHP) is a reagent for the standard treatment of advanced and recurrent colorectal cancer (CRC), although OHP resistance mechanisms are not fully elucidated. We found that OHP-resistant clones derived from HCT116, but not DLD1 were also resistant against the other drugs used for CRC treatment (5-fluorouracil, OHP, and trifluorothymidine) and their xenograft tumors were resistant against OHP treatment. Among the candidate genes derived from microarray analysis using the samples of OHP-resistant cells and their xenografts derived from HCT116, Forkhead box Q1 (FOXQ1) was further assessed for validation of OHP resistance and its association with clinicopathological features. Modification of FOXQ1 via siRNA knockdown and expression vector could not confirm the involvement of FOXQ1 in OHP resistance. In 173 CRC patients, FOXQ1 was upregulated in most CRC tumors compared to normal colonic mucosa. FOXQ1 expression was significantly different by tumor location of the right-sided colon cancer compared with left-sided and rectal cancer. Moreover, expression level was significantly associated with prognosis in advanced and recurrent patients. TCGA data also showed significant association of FOXQ1 expression with tumor location. Our results indicated that FOXQ1 expression is associated with tumor location of right-sided colon, but not with acquisition of OHP resistance in colorectal cancer.

Introduction

Colorectal cancer (CRC) is one of the most common malignancies worldwide\(^1\).

Combination of anticancer drugs (oxaliplatin [OHP], irinotecan [CPT], and 5-fluorouracil [5-FU]) and antibodies targeting vascular endothelial growth factor and epidermal growth factor receptor (EGFR) has become the standard therapy, improving the prognosis of advanced CRC\(^2,3\).

However, advanced CRC is still a fatal disease because resistance against these anticancer drugs is common, despite the initial effectiveness of these drugs. Therefore, elucidating the mechanisms involved in drug resistance is indispensable for further improvements in the prognosis of CRC patients.

The mechanisms of resistance against OHP for advanced CRC treatment have been assessed to improve the prognosis of CRC\(^4\). However, no molecular marker is available for clinical use. Differing from molecular targeted therapy, cytotoxic reagents do not have target genes or proteins. Moreover, multidrug resistance after standard therapy for CRC is also a critical problem, although no molecular marker for multidrug resistance has yet to be identified for clinical use\(^5\).

Tumor location in the right-sided colon was reported as a prognostic marker before the era of molecular targeted therapy, although the background was unclear\(^6\). Recently, EGFR-targeted antibodies have been shown to be ineffective for right-sided colon cancer (RCC) patients regardless of the existence of RAS mutations\(^7–9\). However, the genetic background of patients with advanced RCC suffering from poor prognosis has not yet been elucidated\(^10,11\).

In this study, we established OHP-resistant clones from CRC cell lines (DLD1 and HCT116) to elucidate the mechanism of OHP resistance. Then, we assessed molecular markers associated with OHP resistance in HCT116-derived clones by microarray using both in vitro (cells) and in vivo (xenografts) samples, because the clones derived from HCT116 but not DLD1 also became resistant to the other drugs (5-FU, CPT and trifluorothymidine (TFT)). Among the identified genes, we selected Forkhead box Q1 (FOXQ1) as a candidate gene, because it was reported to be upregulated in CRC tissues and is associated with CRC progression and drug resistance\(^12–19\). Then, we performed validation of FOXQ1 involvement in OHP resistance and assessed the association of FOXQ1 with the clinical features of CRC patients treated at our department and TCGA samples.
Results

Drug sensitivity and proliferation rate

The drug sensitivity of DLD1, HCT116, and OHP-resistant clones is shown in Table 1. IC\textsubscript{50} against the other drugs in OHP-resistant clones derived from DLD1 were less than two times compared to those in DLD1, although there were statistically significant differences between DLD1 and OHP resistant clones in limited cases. On the other side, IC\textsubscript{50} against the other drugs in OHP-resistant clones derived from HCT116 were more than two times compared to those in HCT116 except for HCT/OHP3 against 5-FU. There was statistically significant difference between HCT116 and OHP resistant clones except for HCT/OHP5 against TFT. Thus, OHP-resistant clones derived from HCT116 but not DLD1 had become multidrug resistant. This different pattern of drug sensitivity other than OHP suggested that DLD1 and HCT116 might use different mechanisms for acquisition of OHP resistance. This was also supported by principal component analysis of microarray data of these OHP resistant cells (Figure S1). Therefore, the mechanism used for OHP resistance in HCT116 seems more critical than in DLD1, because this mechanism may induce multidrug resistance during treatments for the patients with advanced CRC.

| Drug            | Cell      | IC\textsubscript{50} (mean ± SD) | *P   | Cell      | IC\textsubscript{50} (mean ± SD) | **P   |
|-----------------|-----------|----------------------------------|------|-----------|----------------------------------|------|
| Oxaliplatin     | DLD1      | 4.38 ± 1.46                      | –    | HCT116    | 0.49 ± 0.22                      | –    |
| (µM)            | DLD/OHP1  | 12.14 ± 3.06                     | 0.005| HCT/OHP1  | 3.13 ± 1.4                       | 0.002|
|                 | DLD/OHP4  | 10.0 ± 3.31                      | 0.049| HCT/OHP3  | 7.73 ± 2.83                      | <0.0001|
|                 | DLD/OHP5  | 18.70 ± 11.04                    | <0.0001| HCT/OHP5  | 5.82 ± 0.87                      | 0.0005|
| 5-fluorouracil  | DLD1      | 0.76 ± 0.19                      | –    | HCT116    | 1.26 ± 0.41                      | –    |
| (µM)            | DLD/OHP1  | 1.23 ± 0.29                      | 0.001| HCT/OHP1  | 3.11 ± 1.03                      | 0.0005|
|                 | DLD/OHP4  | 0.99 ± 0.41                      | 0.10 | HCT/OHP3  | 2.4 ± 0.45                       | 0.01 |
|                 | DLD/OHP5  | 0.84 ± 0.14                      | 0.59 | HCT/OHP5  | 2.71 ± 0.13                      | 0.008|
| Irinotecan      | DLD1      | 2.25 ± 0.37                      | –    | HCT116    | 0.74 ± 0.15                      | –    |
| (µg/ml)         | DLD/OHP1  | 3.35 ± 0.84                      | 0.002| HCT/OHP1  | 2.73 ± 0.44                      | 0.0003|
|                 | DLD/OHP4  | 2.26 ± 0.6                       | 0.94 | HCT/OHP3  | 2.69 ± 0.99                      | 0.0003|
|                 | DLD/OHP5  | 3.16 ± 0.79                      | 0.01 | HCT/OHP5  | 1.79 ± 0.74                      | 0.04 |
| TFT             | DLD1      | 3.41 ± 0.21                      | –    | HCT116    | 1.14 ± 0.58                      | –    |
| (µM)            | DLD/OHP1  | 4.08 ± 0.38                      | 0.11 | HCT/OHP1  | 20.22 ± 6.74                     | 0.0001|
|                 | DLD/OHP4  | 3.72 ± 0.28                      | 0.43 | HCT/OHP3  | 17.67 ± 9.83                     | 0.0005|
|                 | DLD/OHP5  | 4.23 ± 0.75                      | 0.06 | HCT/OHP5  | 5.56 ± 3.34                      | 0.30 |

*P*: statistically evaluated compared to DLD1 by t-test, **P**: statistically evaluated compared to HCT116 by t-test, TFT: Tri fluorothymidine
There was no significant difference between the doubling time of HCT116 and OHP-resistant clones. Doubling time was $19.0 \pm 4.0$ h in HCT116, $19.0 \pm 1.0$ h in HCT/OHP1, $22.5 \pm 2.8$ h in HCT/OHP3, and $18.6 \pm 2.5$ h in HCT/OHP5, respectively (mean ± standard deviation).

**Xenograft model of OHP-resistant clones**

Unlike cell cultures, tumor growth was significantly different in tumors derived from HCT/OHP1 ($P < 0.0001$) and HCT/OHP3 ($P < 0.0001$) compared with those derived from HCT116, although tumor growth was similar between tumors derived from HCT11 and HCT/OHP5 ($P = 0.63$; Fig. 1A). These experiments have been performed twice and showed the same results. Thus, drug resistance induced slower tumor progression, although drug resistance was believed to enhance tumor progression. OHP treatment induced significant growth inhibition ($P = 0.003$) in HCT116-derived tumors with a relatively low tumor growth inhibition (TGI) value of 0.37 (Fig. 1B). OHP treatment was ineffective in both HCT/OHP1-derived and HCT/OHP5-derived tumors with TGI values of 0.12 and 0.07, respectively. CPT treatment induced significant growth inhibition in HCT116-derived tumors ($P < 0.0001$) with a TGI value of 0.8 (Fig. 1B). CPT treatment was statistically effective in HCT/OHP5-derived tumors ($P < 0.0001$) with a TGI value of 0.76. However, CPT treatment was not effective in HCT/OHP1-derived tumors ($P = 0.17$) with a TGI value of 0.53 (Fig. 1C and 1D). These different sensitivities in vivo should be associated with the differences in CPT sensitivity in vitro (more resistance in HCT/OHP1 than in HCT/OHP5; Table 1).

**Candidate genes responsible for OHP resistance**

Eighty-eight genes showed more than two times higher expression in both three OHP resistant clones compared to HCT116 and two tumors derived from OHP resistant clones compared to tumor derived from HCT116 (Table 2). Twenty-nine genes showed less than half of expression in both three OHP resistant clones compared to HCT116 and two tumors derived from OHP resistant clones compared to tumor derived from HCT116 (Table S1). Among these genes, we considered FOXQ1 was the most suitable candidate gene because of its association with drug resistance and tumor progression$^{12,19}$. Upregulation of FOXQ1 in OHP-resistant clones derived from HCT116 and tumors derived from these clones was confirmed by qRT-PCR (Table 3). However, upregulated FOXQ1 expression in tumors derived from OHP resistant clones was not associated with enhanced tumor growth (Fig. 1C and 1D). In DLD1 and its OHP-resistant clones, FOXQ1 expression has not changed by OHP resistance. (Table 3).
Table 2
Upregulated genes in Oxaliplatin resistant clones derived from HCT116

| ADAMTS14 | C6orf15 | CTSD | FOXQ1 | IGFL1 | LGALS9 | PCDH1 | SNAR-G1 |
|----------|---------|------|-------|-------|--------|-------|---------|
| AKR1C1   | CALB2   | CXCL1| GATSL3| IKZF2 | LGALS9C| PMEPA1| SOAT2   |
| AKR1C3   | CCL28   | CXXC4| HERC6 | IL15  | LM07   | PPAP2B| SRPX2   |
| ALCAM    | CD274   | CYP2J2| HOXA3 | IL7   | LOC100507165| PTHLH | STRA6   |
| APOBEC3C | CFH     | DMBT1| HOXB3 | INHBB | LOC643072| RAB27B| TMEM164 |
| APOBEC3D | CLIP4   | DNER | HOXB8 | ITGB2 | MALT1  | RPS6KA2| TMX4    |
| APOBEC3F | CMPK2   | DUSP10| HRCT1| KIAA1244| MAST4 | SAMD9L| WNT7A   |
| APOBEC3G | COL13A1 | EDN1 | HSPA1A| KLF12 | MGP    | SERPINA1| WWC3    |
| ARHGEF37 | COL9A2  | EPSTI1| IFI44 | KRT86 | MIA    | SGK1  | XDH     |
| BCAM     | CPAMD8  | FILIP1L| IFIT3| KRTAP3-1| MILR1 | SH3BP4| XLOC_J2_012847 |
| C10orf11 | CSF2RA  | FOXA1 | IGFBP6| LAMP3 | MX1    | SH3TC2| ZNF365  |

Table 3
Relative FOXQ1 gene expression in vitro and in vivo

| Sample | Oxaliplatin treatment | FOXQ1 expression | Oxaliplatin treatment | FOXQ1 expression |
|--------|-----------------------|------------------|-----------------------|------------------|
| Cell   | HCT116 (-)            | 1 (+)            | 2.6                   |
|        | HCT/OHP1 (-)          | 48.7 (+)         | 92.3                  |
|        | HCT/OHP3 (-)          | 106.4 (+)        | 193.9                 |
|        | HCT/OHP5 (-)          | 15.6 (+)         | 27.1                  |
|        | DLD1 (-)              | 1 (+)            | 0.80                  |
|        | DLD/OHP1 (-)          | 1.30 (+)         | 1.32                  |
|        | DLD/OHP4 (-)          | 0.75 (+)         | 0.55                  |
|        | DLD/OHP5 (-)          | 0.75 (+)         | 0.49                  |
| Tumor  | HCT116 (-)            | 1 Not performed | Not performed         |
|        | HCT/OHP1 (-)          | 8.5 Not performed| Not performed         |
|        | HCT/OHP3 (-)          | 47.4 Not performed| Not performed         |
|        | HCT/OHP5 (-)          | 15.7 Not performed| Not performed         |

Influence of modified FOXQ1 expression on OHP sensitivity

The IC_{50} of OHP in HCT116 cells and HCT/OHP5 cells were 1.35 µM and 7.25 µM following FOXQ1 siRNA knockdown and 1.82 µM and 9.3 µM following the control siRNA treatment (Table 4). The IC_{50} of OHP in HCT116 cells and HCT/OHP cells was 3.43 µM and 18.61 µM following FOXQ1 expression vector treatment and 2.05 µM and 17.94 µM following the control vector (Table 4). Thus, modification of FOXQ1 gene expression could not change IC_{50} of OHP in
both HCT116 cells and HCT/OHP5 cells. In case of DLD1 and DLD/OHP5, IC$_{50}$ of OHP has increased by FOXQ1 siRNA knockdown compared to the control siRNA treatment.

### Table 4

**Effect of FOXQ1 modification on IC50 of Oxaliplatin**

| Cell          | Treatment    | IC50 of Oxaliplatin (µM) |
|---------------|--------------|--------------------------|
| HCT116        | siRNA(Control) | 1.82                     |
| HCT116        | siRNA(FOXQ1)  | 1.35                     |
| HCT/OHP5      | siRNA(Control) | 9.3                      |
| HCT/OHP5      | siRNA(FOXQ1)  | 7.25                     |
| DLD1          | siRNA(Control) | 2.05                     |
| DLD1          | siRNA(FOXQ1)  | 5.04                     |
| DLD/OHP5      | siRNA(Control) | 17.86                    |
| DLD/OHP5      | siRNA(FOXQ1)  | 35.93                    |
| HCT116        | Plasmid(Control) | 5.53                     |
| HCT116        | Plasmid(FOXQ1) | 3.43                     |
| HCT/OHP5      | Plasmid(Control) | 17.94                    |
| HCT/OHP5      | Plasmid(FOXQ1) | 18.61                    |

**Relative FOXQ1 expression in colorectal cancer compared with normal mucosa**

Relative FOXQ1 expression was not influenced by clinical features including age, sex, existence of preoperative chemotherapy, clinical stage, and recurrence/stage IV (Table 5). However, tumor location was significantly associated with FOXQ1 expression (Table 5). FOXQ1 expression in RCC was significantly lower than left-sided colon ($P = 0.006$) and rectal cancer ($P = 0.01$). Microsatellite instability was not associated with FOXQ1 expression. KRAS mutation or BRAF mutation alone was not associated with FOXQ1 expression, although the combined status of KRAS mutation and BRAF mutation was associated with FOXQ1 expression ($P = 0.02$).

**Table 5.** Association of Clinical features and relative FOXQ1 expression in CRC patients
| Clinical features                        | Category       | Number | Relative FOXQ1 expression | P value |
|-----------------------------------------|----------------|--------|---------------------------|---------|
| Age class                               | <65            | 60     | 38.8                      | 0.84    |
|                                         | 65–74          | 53     | 40.7                      |         |
|                                         | 75≤            | 60     | 45.3                      |         |
| Gender                                  | Male           | 100    | 47.6                      | 0.13    |
|                                         | Female         | 73     | 33.5                      |         |
| Tumor location                          | Right-sided colon | 62   | 23.5                      | **0.0088** |
|                                         | Left-sided colon | 36   | 58.1                      |         |
|                                         | Rectum         | 75     | 48.8                      |         |
| Preoperative chemotherapy                | No             | 155    | 43.1                      | 0.34    |
|                                         | Yes            | 18     | 28.7                      |         |
| Clinical stage                          | I              | 16     | 29.3                      | 0.34    |
|                                         | II             | 34     | 53.9                      |         |
|                                         | III            | 36     | 49                        |         |
|                                         | IV             | 87     | 36.1                      |         |
| Stage IV/recurrence                     | Yes            | 101    | 40.7                      | 0.81    |
|                                         | No             | 72     | 43.0                      |         |
| Microsatellite status                   | MSS            | 159    | 41.7                      | 0.92    |
|                                         | MSI            | 13     | 43.4                      |         |
| KRAS mutation                           | No             | 115    | 47.3                      | 0.09    |
|                                         | Yes            | 57     | 30.8                      |         |
| BRAF mutation                           | No             | 158    | 42.8                      | 0.17    |
|                                         | Yes            | 12     | 18.0                      |         |
| KRAS/BRAF mutation                      | No             | 101    | 49.7                      | **0.024** |
|                                         | Yes            | 69     | 28.6                      |         |

In recurrent or stage IV CRC patients, overall survival (OS) was significantly better in those with a relative FOXQ1 expression of $20 \leq$ than in those with < 20 ($P = 0.0007$; Fig. 2A). This significance was also shown when cases were limited to the right-sided colon ($P = 0.014$, Fig. 2B), but not left-sided colon (Fig. 2C) nor rectum (Fig. 2D). Then, the extent of FOXQ1 upregulation was associated with tumor location and poor prognosis in advanced cancer.

**FOXQ1 expression in TCGA samples**

We assessed FOXQ1 expression in colorectal samples to confirm our findings in TCGA samples. Advanced clinical stage was not associated with FOXQ1 expression, although there was significant difference in FOXQ1 expression between stage II and stage IV. Tumor location was significantly associated with FOXQ1 expression (Table 6). FOXQ1 expression in RCC was significantly lower than left-sided colon ($P < 0.0001$) and rectal cancer ($P = 0.0001$). Microsatellite instability was significantly associated with FOXQ1 expression ($P < 0.0001$). KRAS mutation, BRAF
mutation, and the combined status of KRAS mutation and BRAF mutation were significantly associated with FOXQ1 expression. There was no significant difference in OS by extent of FOXQ1 expression. Then, significant association of FOXQ1 expression was shown with tumor location and combined status of KRAS mutation and BRAF mutation both in our department samples and TCGA samples.

Table 6. Association of Clinical features and relative FOXQ1 expression in TCGA data

| Clinical features                | Category           | Number | Δ z-scores relative to normal samples between FOXQ1 and GAPDH | P value |
|--------------------------------|--------------------|--------|-------------------------------------------------------------|---------|
| Age class                       | <65                | 241    | 5.29                                                        | 0.13    |
|                                | 65–74              | 179    | 5.09                                                        |         |
|                                | 75≤                | 167    | 4.60                                                        |         |
| Gender                          | Male               | 309    | 5.13                                                        | 0.47    |
|                                | Female             | 278    | 4.93                                                        |         |
| Tumor location                  | Right-sided colon  | 247    | 4.15                                                        | <0.0001 |
|                                | Left-sided colon   | 144    | 6.08                                                        |         |
|                                | Rectum             | 160    | 5.55                                                        |         |
| Clinical stage                  | I                  | 102    | 5.11                                                        | 0.006   |
|                                | II                 | 218    | 4.40                                                        |         |
|                                | III                | 171    | 5.25                                                        |         |
|                                | IV                 | 84     | 6.14                                                        |         |
| Microsatellite status           | MSS/MSI-L          | 504    | 5.43                                                        | <0.0001 |
|                                | MSI-H              | 83     | 2.47                                                        |         |
| KRAS mutation                   | No                 | 397    | 5.25                                                        | 0.024   |
|                                | Yes                | 193    | 4.58                                                        |         |
| BRAF mutation                   | No                 | 534    | 5.20                                                        | 0.0002  |
|                                | Yes                | 56     | 3.42                                                        |         |
| KRAS/BRAF mutation              | No                 | 342    | 5.53                                                        | <0.0001 |
|                                | Yes                | 248    | 4.36                                                        |         |

Discussion

Here we assessed the mechanisms associated with OHP resistance in CRC cells. We found that OHP resistant clones derived from DLD1 and HCT116 showed different patterns of drug sensitivity against 5-FU, CPT, and TFT, which were used for CRC treatment after OHP resistance. We found that OHP resistant clones derived from HCT116 were also resistant against 5-FU, CPT, and TFT, although OHP resistant clones derived from DLD1 showed the same sensitivity
as DLD1. Then, the mechanisms used in HCT116 seemed more critical than DLD1, because further treatments after OHP resistance maybe ineffective. These data indicated that there might be several mechanisms for OHP resistance in CRC.

Then, we further assessed the genes which have changed significantly in three OHP resistant clones compared to parental HCT116 cells both in vitro and in vivo using microarray analysis. Among the genes significantly changed in three OHP resistant clones compared to HCT116, we selected FOXQ1 as the candidate gene associated with acquisition of OHP resistance. This is because upregulation of FOXQ1 in CRC tissue and its association with tumor progression and drug sensitivity has been reported\cite{12-18}. However, expression and influence of FOXQ1 on CRC cell lines were not consistent in these reports.

In this study, inhibition of FOXQ1 expression did not change IC$_{50}$ of OHP in HCT116 and its OHP resistant clone, which was not consistent with previous report using SW480 cells\cite{15}. Enhancement of FOXQ1 by expression vector also could not change IC$_{50}$ of OHP. Thus, we considered that upregulation of FOXQ1 in OHP resistant clones derived from HCT116 might result from OHP treatment but was not the cause of OHP resistance. These results also showed the limitations of exploring drug resistance mechanisms using drug-resistant cells.

Regarding influence of FOXQ1 expression on tumor progression, tumor growth derived from OHP resistant clones was similar or downregulated compared to those derived from HCT116. These data were consistent\cite{14,16} and inconsistent\cite{12,18} with the previous reports, although upregulation of FOXQ1 was acquired by drug resistance in this study and by genetic modification in the previous reports. In clinical samples of our department and TCGA, FOXQ1 expression was not associated with clinical stage. These data are not inconsistent with the previous report\cite{15}.

On the other hand, upregulation of FOXQ1 in CRC tissue compared with normal tissue was consistent with previous studies\cite{12-15,17,18}. Moreover, we found that FOXQ1 expression differed by tumor location both in our cohort and in TCGA samples. This is the first report indicating the association of FOXQ1 with tumor location of RCC, which was considered prognostic marker in advanced and recurrent CRC patients\cite{6-9}. In advanced and recurrent CRC patients of our cohort, FOXQ1 expression was associated with overall survival of RCC, which was not shown in stage IV patients of TCGA samples. This difference in TCGA samples, but not in our cohort, FOXQ1 expression was significantly lower in MSI-H patients compared to MSS patients. In patients with KRAS or BRAF mutations, FOXQ1 expression was significantly lower than those without mutations in both our cohort and TCGA samples. The differences between our cohort and TCGA samples include more frequency of stage IV and recurrent patients in our cohort.

Our study has several limitations. First, we have not elucidated the mechanisms of OHP resistance, although this study started this purpose at first. FOXQ1 was not associated with acquisition of OHP resistance in DLD1 and HCT116 cells, and genes other than FOXQ1 have not yet been assessed. Second, we have not assessed the mechanisms associated with the differential expression of FOXQ1 by tumor location, although these may elucidate the reason of tumor location of RCC for the prognostic marker of CRC.

In conclusion, our study shows that several mechanisms are associated with acquisition of OHP resistance and FOXQ1 expression is associated with tumor location of RCC. Further study is necessary to elucidate these mechanisms.

**Methods**

**Drugs and chemicals**
OHP, CPT, and 5-FU were purchased from NIPRO (Osaka, Japan), TOWA Pharmaceutical Co., (Kadoma, Japan), and KYOWA KIRIN (Tokyo, Japan), respectively. TFT was purchased from Tokyo Chemical Industry Co. (Tokyo, Japan) and dissolved in DMSO at a concentration of 20 mM. All drugs were diluted in culture medium immediately before use.

**Cell lines and cloning of drug-resistant cells**

Human CRC cell line DLD1 was purchased from Japan Health Sciences Foundation (Osaka, Japan). Human CRC cell line HCT116 was a kind gift from Dr. Yamamoto (Department of Surgery and Clinical Oncology, Osaka University Graduate School of Medicine, Osaka, Japan). These cells were authenticated by American Type Culture Collection using DNA profiling (Manassas, Virginia, USA). Cells were maintained in DMEM supplemented with 10% fetal bovine serum, 10,000 units penicillin, 10 mg/ml streptomycin, and 25 µg/ml amphotericin B. Culture media and fetal bovine serum were obtained from Life Technologies Japan (Tokyo, Japan). All cells were grown at 37°C in a humidified incubator with 5% CO₂. DLD1 and HCT116 cells were co-cultured with 20 µM OHP or 10 µM OHP, respectively. Then, OHP-resistant clones were isolated by limited dilutions and named as DLD/OHP1, DLD/OHP4, and DLD/OHP5, when derived from DLD1, and HCT/OHP1, HCT/OHP3, and HCT/OHP5, when derived from HCT116.

**Drug sensitivity and proliferation rate**

Cells were seeded in 200 µl medium in 96-well flat-bottom plates at a density of 2 × 10³ cells per well. The next day, the medium was removed and serial dilutions of OHP (0.1 – 500 µM), 5-FU (0.1 – 500 µM), CPT (0.1 – 100 µg/ml), and TFT (0.1 – 100 µM) were added to each well. After 96 h, cells were counted using a cell counting kit (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. Half maximal inhibitory concentration (IC₅₀) values were calculated as the concentrations that corresponded to a 50% reduction in cellular proliferation compared with untreated cells. The proliferation rate was calculated as the doubling time of the cell number as measured by the cell counting kit. Experiments were performed independently at least three times, and data are shown as means ± standard deviations.

**Animal experiments**

Four-week-old female BALB/cAJcl-nu/nu mice were purchased from Japan Clea Inc. (Tokyo, Japan). Mouse care and experiments were performed under specific pathogen-free conditions at the Institute of Experimental Animal Science, Hyogo College of Medicine. All animal protocols were approved by the Institutional Animal Care and Use Committee of Hyogo College of Medicine (12–067). All animal experiments were performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of Hyogo College of Medicine. Then, the study was carried out in compliance with the ARRIVE guidelines (http://www.nc3rs.org.uk/page.asp?id=1357).

To assess the tumor growth of xenografts derived from HCT116 and OHP-resistant clones, a total of 5 · 10⁶ HCT116 cells and OHP-resistant clones (HCT/OHP1, HCT/OHP3, and HCT/OHP5 cells) were subcutaneously inoculated in the right and left flanks of seven mice, respectively. Tumor size was measured twice a week. Tumor volume was calculated as a × b² (where a represents the tumor length and b represents its width).

To assess OHP resistance in xenografts, a total of 5 · 10⁶ HCT116 cells and OHP-resistant clone HCT/OHP5 cells were subcutaneously inoculated in both flanks of 12 mice (24 sites). Xenograft tumors derived from HCT/OHP1 cells were minced and inoculated into both flanks of the 12 mice because the growth of HCT/OHP1-derived xenograft tumors was so slow compared with that of HCT116 and HCT/OHP5. Tumor size was measured twice a week and tumor volume was calculated as described above. When the tumor diameter was > 5 mm, the mice were randomized into no treatment (control) or drug treatment groups (5 mg/kg OHP or 10 mg/kg CPT injected intraperitoneally twice a week for a total of five weeks, four mice [eight tumors] per each group) after adjusting the mean tumor volume among the
groups. The rate of TGI was calculated as follows: 1 – (increase in tumor volume in the drug treatment group)/(increase in tumor volume in the control group). TGI was assessed after the completion of drug treatment.

**Microarray data analysis**

A total of $1 \cdot 10^6$ HCT116, HCT/OHP1, HCT/OHP3, and HCT/OHP5 cells were seeded onto P10 tissue culture plates. Twenty-four hours later, total RNA was extracted using an RNeasy Mini kit (Qiagen K.K., Tokyo, Japan) according to the manufacturer's instructions. Total RNA was also extracted from human tumor xenografts derived from HCT116, HCT/OHP1, and HCT/OHP5 without drug treatment.

Gene expression profiles were analyzed by Agilent SurePrint G3 Human GE 8x60K v2 Microarray kit (Agilent). The data set is available at Gene Expression Omnibus under accession number GSE77932 for cell experiments and GSE124808 for tumor experiments.

Signal data were imported into GeneSpring (Agilent) for analysis. Signal evaluation was performed depending on signal uniformity and the significant difference between signal and background. Signal data were normalized by the 75th percentile among arrays. Genes for which signal data were $\geq 2$ in OHP resistance clones compared to HCT116 both *in vitro* and *in vivo* were selected as upregulated genes. Genes for which signal data were $0.5 \geq$ in OHP resistance clones compared to HCT116 both *in vitro* and *in vivo* were selected as downregulated genes.

**Validation of FOXQ1 involvement in OHP resistance**

Among the upregulated and downregulated genes, *FOXQ1* was selected as a candidate gene because of its association with drug resistance and tumor progression. FOXQ1 expression in cells and tumors was evaluated by quantitative real-time reverse transcription PCR (qRT-PCR), as previously described. The primer sequences were FOXQ1-forward: CTTCCCTCCCCCCTAACGATCAT and FOXQ1-reverse: ATGCCACATACGTACACGGATG. GAPDH was used as an internal control. ΔCT was calculated using the CT (Threshold cycle) value of FOXQ1 and that of GAPDH in each sample. Data was calculated from triplicate wells.

The influence of FOXQ1 on OHP resistance was assessed by inhibition of FOXQ1 expression by siRNA knockdown (siRNA (h): sc-60660; Santa Cruz, Dallas, USA) and control siRNA-A (sc-37007; Santa Cruz). Hily MAX was used for transfection (Dojindo). A total of $8 \times 10^3$ HCT116, HCT/OHP5, DLD1, and DLD/OHP5 cells in a volume of 200 µl medium were seeded into 96-well flat-bottom plates. The next day, the medium was removed and serial dilutions of OHP (0.1 − 100 µM), 1.2 µL Hily Max, and 20 pmol siRNA were added to each well in a total volume of 200 µl medium. The influence of FOXQ1 expression on OHP resistance was also assessed by enhancement of FOXQ1 using FOXQ1 expression plasmid and control plasmid, which were constructed previously. Then $8 \times 10^3$ HCT116 and HCT/OHP5 cells in 200 µl medium were seeded into 96-well flat-bottom plates. The next day, the medium was removed and serial dilutions of OHP (0.1 − 100 µM), 1.2 µL Hily Max, and 0.2 µg FOXQ1 expression plasmid or control plasmid were added to each well in a total volume of 200µl medium. After 48 h of FOXQ1 expression modification, cells were counted using a cell counting kit according to the manufacturer's instructions and $IC_{50}$ was measured as described above.

**Association of FOXQ1 expression with clinical features in CRC patients**

Specimens were collected from 173 CRC patients who underwent surgery at our department. All protocols were approved by the ethics committee of Hyogo College of Medicine and all patients provided written informed consent (No. 0120 by the Institutional Review Board of Hyogo College of Medicine). All experiments were performed depending on the Declaration of Helsinki, the guidelines and the associated laws in Japan. The CRC specimens consisted of 155
tumors without chemotherapy, 13 tumors after chemotherapy including OHP, and five after chemoradiotherapy. The CRC specimens were obtained with adjacent normal mucosal tissues for comparison and stored at −80°C in RNAlater before use (Qiagen K.K.). Relative FOXQ1 expression was assessed by ΔΔCT generated from difference of ΔCT values in CRC tumors and normal mucosal tissue.

**Association of FOXQ1 expression with clinical features in CRC patients of TCGA data**

We further assessed FOXQ1 expression in CRC samples of TCGA. RNA-seq data of colorectal adenocarcinoma were collected from TCGA PanCancer Atlas in cBioPortal for Cancer Genomics (https://www.cbioportal.org/study/summary?id=coadread_tcga_pan_can_atlas_2018). Differences between mRNA expression z-scores of FOXQ1 relative to normal samples and those of GAPDH relative to normal scores were used to evaluate association of FOXQ1 expression with clinical features as in CRC patients of our department.

**Data analysis**

Differences in IC50 values and doubling times between OHP-resistant clones and parental cells were assessed by t-test. Tumor volumes of xenografts at seven weeks after inoculation were assessed between each clone and HCT116 cells by t-test. The tumor volumes by OHP treatment were also compared between the control and treatment groups using a t-test. Association of FOXQ1 expression with clinical features was assessed by t-test in case of two categories and by analysis of variance in case of more than three categories. Influence of FOXQ1 expression on overall survival was assessed by Kaplan-Meier curve and evaluated by Log-rank test. A P value of <0.05 was considered significant for all analyses.

**Declarations**

**Acknowledgements**

We thank Ms. Miki Fukumoto, MS. Takako Ishikawa, Ms. Shino Tanaka, the members of Center for Comparative Medicine and Joint-Use Research facilities at Hyogo College of Medicine for collecting data. This work was supported by JSPS KAKENHI grant number 26462031, JP17K10658 and Grant-in-Aid for Researchers, Hyogo College of Medicine, 2012. We thank Edanz Group (www.edanzediting.com/ac) for editing a draft of this manuscript.

**Author Contributions**

TY conceived the study; TY, TK, AY performed experiments; TY, YT, JS, KK, MY, AB, KK, NB, MI collected samples and data, TY, SK, TK, KN, NT analyzed and interpreted data; TY wrote the manuscript; all authors reviewed the manuscript.

**Competing interests**

TY is a temporary employee of Shionogi & CO., LTD.

**Data Availability**

The data that support the findings of this study are available from the corresponding author upon reasonable request.

**References**

1. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *Cancer J. Clin.* 68, 394-424
2. Fakih, M. G. Metastatic colorectal cancer: current state and future directions. *Clin. Oncol.* 33, 1809-1824 (2015).

3. Piawah, S. & Venook, A. P. Targeted therapy for colorectal cancer metastases: A review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer. *Clin. Oncol.* 125, 4139-4147 (2019).

4. Martinez-Balibrea, E. *et al.* Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance. *Cancer Ther.* 14, 1767-1776 (2015).

5. Kibria, G., Hatakeyama, H. & Harashima, H. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system. *Pharm. Res.* 37, 4-15 (2014).

6. Meguid, R. A., Slidell, M. B., Wolfgang, C. L., Chang, D. C. & Ahuja, N. Is there a difference in survival between right-versus left-sided colon cancers? *Surg. Oncol.* 15, 2388-2394 (2018).

7. Brulé, S. Y. *et al.* Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. *J. Cancer* 51, 1405-1414 (2015).

8. Loupakis, F. *et al.* Primary tumor location as a prognostic factor in metastatic colorectal cancer. *Natl. Cancer Inst.* 107, dju427 (2015).

9. Holch, J. W., Ricard, I., Stintzing, S., Modest, D. P. & Heinemann, V. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. *J. Cancer* 70, 87-98 (2017).

10. Yaeger, R. *et al.* Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. *Cancer Cell* 33, 125-136 (2018).

11. Imperial, R. *et al.* Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. *Cancer* 17, 177 (2018).

12. Liu, J. Y., Wu, X. Y., Wu, G. N., Liu, F. K. & Yao, X. Q. FOXQ1 promotes cancer metastasis by PI3K/AKT signaling regulation in colorectal carcinoma. *J. Transl. Res.* 9, 2207-2218 (2017).

13. Li, Y., Zhang, Y., Yao, Z., Li, S., Yin, Z. & Xu, M. Forkhead box Q1: A key player in the pathogenesis of tumors (Review). *Int J Oncol* 49, 51-58 (2016).

14. Weng, W., Okugawa, Y., Toden, S., Toiyama, Y., Kusunoki, M. & Goel, A. FOXM1 and FOXQ1 Are Promising Prognostic Biomarkers and Novel Targets of Tumor-Suppressive miR-342 in Human Colorectal Cancer. *Cancer Res.* 22, 4947-4957 (2016).

15. Peng, X. *et al.* FOXQ1 mediates the crosstalk between TGF-β and Wnt signaling pathways in the progression of colorectal cancer. *Cancer Biol. Ther.* 16, 1099-1109 (2015).

16. Abba, M. *et al.* Unraveling the role of FOXQ1 in colorectal cancer metastasis. *Cancer Res.* 11, 1017-1028 (2013).

17. Christensen, J., Bentz, S., Sengstag, T., Shastrī, V. P. & Anderle, P. FOXQ1, a novel target of the Wnt pathway and a new marker for activation of Wnt signaling in solid tumors. *PLoS One* 8, e60051 (2013).

18. Kaneda, H. *et al.* FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. *Cancer Res.* 70, 2053-2063 (2010).

19. Bieller, A. *et al.* Isolation and characterization of the human forkhead gene FOXQ1. *DNA Cell Biol.* 20, 555-561 (2001).

20. Yamano, T. *et al.* Splicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy. *Oncotarget* 10, 352-367 (2019).